

# HHS Interim Committee - May 2019

**Edward Redd MD**

Chair of Cannabinoid Product Board  
Logan, UT

# Cannabinoid Product Board – 2018-2019

- **Ed Redd, MD** (Board Chair)
  - Internal Medicine Physician
- **Michael J. Crookston, MD, FAPA, FASAM** (Board Co-chair)
  - Medical Director, Adult Dayspring
- **Karen S. Wilcox, Ph.D.**
  - Professor and Chair, Department of Pharmacology and Toxicology, University of Utah
  - Laboratory of Glial/Neuronal Interactions in Epilepsy
- **Erik Christensen, M.D.**
  - Chief Medical Examiner, Utah Department of Health
- **Glen R. Hanson, D.D.S., Ph.D.**
  - Senior Advisor, NIH, College Of Pharmacy
  - Director, Utah Addiction Center
  - Professor of Pharmacology and Toxicology, University of Utah
- **Mark Munger, Pharm.D.**
  - Professor of Pharmacotherapy
  - Adjunct Professor, Internal Medicine, University of Utah
- **Perry Renshaw, M.D., Ph.D., M.B.A.**
  - Medical Director of the VISN 19 Mental Illness Research,
  - Education and Clinical Center (MIRECC)
  - Salt Lake City Veterans Affairs Medical Center

## Additional help from others:

- Rachael Belcher – Roseman School of Pharmacy
- Dr Joel Ehrenkranz – endocrinologist - Intermountain Healthcare
- Dr Perry Fine – anesthesia - pain management - UUMC
- Dr Brian Zehnder – family practice
- Dr Lauren Heath – Pharm D - UUMC
- Dr Katherine Carlson MD, MS – psychiatry – SUD expertise - UUMC
- Staff from UDOH

- **1690 Section 44. Section 26-61-202 is amended to read:**
- **1691 26-61-202. Cannabinoid Product Board -- Duties.**
- 1692 (1) The board shall review any available scientific research related to the human use of
- 1693 cannabis, a cannabinoid product, or an expanded cannabinoid product that:
- 1694 (a) was conducted under a study approved by an IRB; or
- 1695 (b) was conducted or approved by the federal government.
- 1696 (2) Based on the research described in Subsection (1), the board shall evaluate the
- 1697 safety and efficacy of cannabis, cannabinoid products, and expanded cannabinoid products,
- 1698 including:
- 1699 (a) medical conditions that respond to cannabis, cannabinoid products, and expanded
- 1700 cannabinoid products;
- 1701 (b) cannabis and cannabinoid dosage amounts and medical dosage forms; [and]
- 1702 (c) interaction of cannabis, cannabinoid products, and expanded cannabinoid products
- 1703 with other treatments[.]; and
- 1704 (d) contraindications, adverse reactions, and potential side effects from use of cannabis,
- 1705 cannabinoid products, and expanded cannabinoid products.

- 1706 (3) Based on the board's evaluation under Subsection (2), the board shall develop
- 1707 guidelines for treatment with cannabis, a cannabinoid product, and an expanded cannabinoid
- 1708 product that include:
- 1709 (a) a list of medical conditions, if any, that the board determines are appropriate for
- 1710 treatment with cannabis, a cannabis product, a cannabinoid product, or an expanded
- 1711 cannabinoid product[.];
- 1712 (b) a list of contraindications, side effects, and adverse reactions that are associated
- 1713 with use of cannabis, cannabinoid products, or expanded cannabinoid products; and
- 1714 (c) a list of potential drug-drug interactions between medications that the United States
- 1715 Food and Drug Administration has approved and cannabis, cannabinoid products, and
- 1716 expanded cannabinoid products.
- 1717 (4) The board shall submit the guidelines described in Subsection (3) to:
- 1718 (a) the director of the Division of Occupational and Professional Licensing; and
- 1719 (b) the Health and Human Services Interim Committee.
- 1720 (5) The board shall report the board's findings before November 1 of each year to the
- 1721 Health and Human Services Interim Committee.



Public Release

# *Health Effects of Cannabis and Cannabinoids*

*Current State of  
Evidence and  
Recommendations for  
Research*

This report will be available to  
download as a free pdf:  
**[Nationalacademies.org/CannabisHealthEffects](https://www.nationalacademies.org/CannabisHealthEffects)**

*The National Academies of*  
SCIENCES • ENGINEERING • MEDICINE



# American Herbal Pharmacopoeia®

## *Cannabis Inflorescence and Leaf* *Cannabis L.*

STANDARDS OF IDENTITY, ANALYSIS, AND  
QUALITY CONTROL

### Editors

Roy Upton RH DAyu  
American Herbal Pharmacopoeia  
Scotts Valley, CA

Aviva Rotman MD CPM  
American Herbal Pharmacopoeia  
Lenox, MA

Lyle Craker PhD  
University of Massachusetts  
Amherst, MA

### Technical Advisors and Editors

Mahmoud ElSohly PhD  
University of Mississippi  
University, MS

Elhan Russo MD  
CW Pharmaceuticals plc.  
Salisbury, UK

Michelle Sexton ND BS  
Americans for Safe Access  
Washington, DC

### Technical Contributor

Jakub Marcin PhD  
Temple University School of Medicine  
Philadelphia, PA

### Associate Editor

Pavel Asentiev MS  
American Herbal Pharmacopoeia  
Scotts Valley, CA

### Research Associate

Diana Swisher MA  
American Herbal Pharmacopoeia  
Scotts Valley, CA





# INFORMATION FOR HEALTH CARE PROFESSIONALS

---

250 pages of  
detailed  
information.

## **Cannabis (marihuana, marijuana) and the cannabinoids**

Dried or fresh plant and oil administration by ingestion or other means  
Psychoactive agent



Government  
of Canada

Gouvernement  
du Canada

Canada



Goals for  
Cannabinoid  
Product Board  
before  
November 1,  
2019

- Put together the “package insert” for Utah
- Assist UDOH as requested
  - Review of potential on-line CME (continuing medical education)
  - Consistency between CME and “package insert”